Literature DB >> 17336197

Adverse reactions to the Bacillus Calmette-Guerin vaccine in HIV-positive infants.

Angus Alexander1, Heinz Rode.   

Abstract

BACKGROUND: The Bacillus Calmette-Guerin (BCG) vaccine is routinely administered to newborn infants in South Africa. In 2000, a new vaccine, the Danish 1331 strain, was introduced into the Western Cape region. Red Cross Children's Hospital subsequently documented an increase in the number of complications arising from the new vaccine. Since 2004, HIV-positive infants have been treated with highly active antiretroviral therapy (HAART). Coinciding with the roll out of HAART there has been a significant and apparently paradoxical worsening of the complications of the BCG vaccine.
METHODS: A retrospective analysis of all HIV-positive infants referred to the surgical department for management of BCG vaccine complications.
RESULTS: Fifteen infants were included in this study; they were all HIV-positive. Fourteen infants received HAART. In 10 patients, the implementation of HAART predated the complications of the BCG vaccine by an average of 1.4 months.
CONCLUSION: We believe this to be the first description of BCG-associated immune reconstitution inflammatory syndrome. The implications for the operating surgeon are the unique management strategies that should be applied to this disease process and the ongoing research to determine which of these strategies is the most effective.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17336197     DOI: 10.1016/j.jpedsurg.2006.10.059

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  4 in total

1.  Reduced rate of adverse reactions to the BCG vaccine in children exposed to the vertical transmission of HIV infection and in HIV-infected children from an endemic setting in Brazil.

Authors:  Regina Célia de Souza Campos Fernandes; Luciana Cordeiro de Araújo; Enrique Medina-Acosta
Journal:  Eur J Pediatr       Date:  2008-09-03       Impact factor: 3.183

2.  Comparison of in-hospital morbidity and mortality in HIV-infected and uninfected children after surgery.

Authors:  Jonathan S Karpelowsky; Alastair J W Millar; Nelleke van der Graaf; Guido van Bogerijen; Heather J Zar
Journal:  Pediatr Surg Int       Date:  2012-08-26       Impact factor: 1.827

3.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

4.  Nanocages engineered from Bacillus Calmette-Guerin facilitate protective Vγ2Vδ2 T cell immunity against Mycobacterium tuberculosis infection.

Authors:  Jiang Pi; Zhiyi Zhang; Enzhuo Yang; Lingming Chen; Lingchan Zeng; Yiwei Chen; Richard Wang; Dan Huang; Shuhao Fan; Wensen Lin; Hongbo Shen; Jun-Fa Xu; Gucheng Zeng; Ling Shen
Journal:  J Nanobiotechnology       Date:  2022-01-15       Impact factor: 10.435

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.